Nipt denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for nipt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied NIPT as Not FDA-Approved

This denial reflects an important regulatory nuance: non-invasive prenatal testing (NIPT) is a laboratory-developed test (LDT) regulated under the Clinical Laboratory Improvement Amendments (CLIA) framework rather than the FDA's premarket approval or 510(k) clearance pathway. Many NIPT assays are not FDA-approved in the traditional device sense, but they are performed in CLIA-certified high-complexity laboratories and have been commercially available for years with extensive peer-reviewed validation.

When UHC applies a "not FDA-approved" criterion to a laboratory test, they may be conflating the FDA device pathway with the CLIA laboratory licensure pathway, or they may have an explicit coverage policy excluding LDTs that lack FDA clearance. Clarifying the regulatory status of the specific laboratory and test platform is the first step in the appeal.

## Federal Appeal Framework

• ACA §2719 external review: available after exhausting internal appeals for most fully insured non-grandfathered plans. Confirm the external-review deadline on your denial letter — the window is approximately four months from the final internal denial.
• ERISA §503: governs self-funded plans after internal exhaustion.
• Expedited review: request this if gestational timing makes standard timelines clinically inadequate.

## Appeal Process and Timeline

1. Request from UHC the exact policy provision under which the not-FDA-approved criterion was applied, and confirm whether the plan distinguishes between FDA device clearance and CLIA laboratory certification. 2. Obtain from the testing laboratory their CLIA certification documentation and any FDA 510(k) clearance or breakthrough device designation they hold. 3. File a Level 1 internal appeal within the deadline on your denial notice. 4. Attach the laboratory's regulatory credentials and the clinical indication documentation together.

## Documentation to Gather

• Laboratory regulatory credentials: CLIA certificate, any FDA clearance or authorization held by the specific test platform or laboratory, and documentation that the laboratory meets the plan's quality standards.
• Clinical indication documentation: chart entries establishing the clinical reason the test was ordered, consistent with recognized professional society guidance (ACOG/SMFM).
• Ordering provider letter: addresses the regulatory status of the test, its clinical validation, and its endorsement by professional societies as an appropriate clinical option.
• Professional society guidance: the current ACOG/SMFM committee opinion or guideline recognizing NIPT as an accepted clinical tool for the applicable indication.

## Criteria-Mapping Structure

Your criteria table should map the specific FDA-approval language in UHC's policy to the actual regulatory status of the laboratory and test: CLIA certification level, any FDA clearance or authorization, and professional society recognition. Then include the standard clinical criteria table showing the chart facts supporting the indication. A well-structured appeal that addresses the regulatory-status question directly — rather than only the clinical question — is most likely to succeed on this denial type.